Please assess the completion status of the following clinical trial:

Trial Title: Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 38-46; BMI 18.5-24.0kg/m2; intended to undergo PGT-A; GnRH Antagonist protocol for ovarian stimulation; normal semen analysis for the male partner~Exclusion Criteria:~* Endometriosis grade 3 or higher, untreat hydrosalpinx;~* Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex);~* Untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)~* Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;~* Women who received other supplement drugs during ovarian stimulation

- Gender: FEMALE
- Minimum Age: 38 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- GH group (Type: EXPERIMENTAL): Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation
- Control group (Type: ACTIVE_COMPARATOR): No Growth Hormone supplement, GnRH antagonist protocol for ovarian stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).